What Is Mounjaro For? The FDA-Approved Indication, the Off-Label Reality, and What the Clinical Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is FDA-approved exclusively for type 2 diabetes management as an adjunct to diet and exercise, not for weight loss in non-diabetic patients
• The same active ingredient is sold as Zepbound for obesity treatment, creating a regulatory distinction without a meaningful clinical difference
• In the SURPASS trials, tirzepatide reduced A1C by 1.9 to 2.4 percentage points and produced 15 to 22% total body weight loss depending on dose
• Compounded tirzepatide serves patients who cannot access brand-name versions due to cost, insurance coverage gaps, or ongoing FDA shortage designations

Direct answer (40-60 words)

Mounjaro is FDA-approved for treating type 2 diabetes in adults as an adjunct to diet and exercise. Its active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist that lowers blood sugar and causes significant weight loss. The identical molecule is marketed as Zepbound for obesity treatment in non-diabetic patients.

Table of contents

1. The FDA-approved indication: what the label actually says
2. How tirzepatide works: the dual-agonist mechanism
3. The clinical trial data: diabetes outcomes from SURPASS
4. The weight loss effect: why the same drug has two brand names
5. Off-label prescribing: when providers use Mounjaro for weight loss
6. Mounjaro vs Zepbound: identical molecule, different regulatory paths
7. What most articles get wrong about GIP receptor activation
8. The compounded tirzepatide option: when and why it's prescribed
9. Who should not take Mounjaro or tirzepatide
10. The dosing ladder: how treatment typically progresses
11. Insurance coverage patterns: why the brand name matters
12. FAQ
13. Sources

The FDA-approved indication: what the label actually says

Mounjaro received FDA approval on May 13, 2022, for a single indication: improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

The approval was based on the SURPASS clinical trial program, which enrolled 6,600+ patients across five phase 3 trials. The label specifies:

• Population: Adults with type 2 diabetes
• Use: Adjunct to diet and exercise
• Not indicated for: Type 1 diabetes, diabetic ketoacidosis, weight loss in non-diabetic patients, or as a first-line therapy when diet and exercise alone would suffice

The label explicitly states Mounjaro has not been studied in patients with a history of pancreatitis and carries a boxed warning about thyroid C-cell tumors observed in rodent studies (though no human cases have been causally linked to tirzepatide as of April 2026).

This narrow indication creates a regulatory oddity: the medication produces more weight loss than any other diabetes drug in history, but prescribing it primarily for weight loss in a non-diabetic patient is technically off-label use.

The FDA resolved this by approving the same molecule under a different brand name (Zepbound) for obesity treatment in November 2023, creating two parallel regulatory pathways for the same active pharmaceutical ingredient.

How tirzepatide works: the dual-agonist mechanism

Tirzepatide is the first and only dual GLP-1 and GIP receptor agonist approved for clinical use. Understanding what that means requires breaking down both receptor systems.

GLP-1 (glucagon-like peptide-1) receptors are found primarily in:

• Pancreatic beta cells (insulin secretion)
• Pancreatic alpha cells (glucagon suppression)
• The brain's appetite centers (satiety signaling)
• The stomach (gastric emptying control)

When tirzepatide binds to GLP-1 receptors, it triggers glucose-dependent insulin release (meaning insulin only increases when blood sugar is elevated), suppresses glucagon (which normally raises blood sugar), slows gastric emptying (making you feel full longer), and directly signals satiety in the hypothalamus.

GIP (glucose-dependent insulinotropic polypeptide) receptors are found in:

• Pancreatic beta cells (insulin secretion)
• Adipose tissue (fat cells)
• Bone tissue
• The brain

GIP's role is more complex and was historically misunderstood. Early research suggested GIP might promote fat storage, leading some researchers to design GIP antagonists (blockers) for weight loss. Tirzepatide does the opposite: it's a GIP agonist (activator).

The breakthrough insight came from studies showing that GIP activation in the context of simultaneous GLP-1 activation enhances insulin sensitivity, reduces food intake beyond what GLP-1 alone achieves, and increases energy expenditure in adipose tissue (Frias et al., Lancet 2021).

The net effect: tirzepatide produces roughly 50% more weight loss than semaglutide (a pure GLP-1 agonist) at comparable doses, while achieving similar or better glycemic control.

[Diagram suggestion: dual-receptor binding illustration showing tirzepatide molecule binding to both GLP-1 and GIP receptors on a pancreatic beta cell, with arrows indicating insulin secretion, glucagon suppression, and downstream metabolic effects]

The clinical trial data: diabetes outcomes from SURPASS

The SURPASS program included five phase 3 trials comparing tirzepatide to placebo, semaglutide, insulin degludec, and insulin glargine in patients with type 2 diabetes.

SURPASS-1 (N = 478, 40 weeks, treatment-naive patients):

• Tirzepatide 5 mg: A1C reduction 1.87%, weight loss 7.0 kg
• Tirzepatide 10 mg: A1C reduction 1.89%, weight loss 7.8 kg
• Tirzepatide 15 mg: A1C reduction 2.07%, weight loss 9.5 kg
• Placebo: A1C reduction 0.04%, weight loss 0.7 kg

SURPASS-2 (N = 1,879, 40 weeks, head-to-head vs semaglutide 1 mg):

• Tirzepatide 5 mg: A1C reduction 2.01%, weight loss 7.6 kg
• Tirzepatide 10 mg: A1C reduction 2.24%, weight loss 9.3 kg
• Tirzepatide 15 mg: A1C reduction 2.30%, weight loss 11.2 kg
• Semaglutide 1 mg: A1C reduction 1.86%, weight loss 5.7 kg

SURPASS-3 (N = 1,444, 52 weeks, vs insulin degludec):

• Tirzepatide 5 mg: A1C reduction 1.93%, weight loss 7.5 kg
• Tirzepatide 10 mg: A1C reduction 2.20%, weight loss 10.5 kg
• Tirzepatide 15 mg: A1C reduction 2.37%, weight loss 12.9 kg
• Insulin degludec: A1C reduction 1.34%, weight gain 1.9 kg

The pattern is consistent: tirzepatide produces A1C reductions of 1.9 to 2.4 percentage points across all doses, with dose-dependent weight loss ranging from 7 to 13 kg (15 to 29 pounds) over 40 to 52 weeks in diabetic populations.

A pooled analysis (Ludvik et al., Diabetes Obesity and Metabolism 2023) showed that 51% of patients on tirzepatide 15 mg achieved an A1C below 5.7% (the threshold for diabetes remission) compared to 20% on semaglutide 1 mg and 4% on insulin.

The weight loss effect: why the same drug has two brand names

The weight loss observed in the SURPASS trials was not a secondary endpoint. It was a primary efficacy measure in several trials, reflecting the understanding that weight reduction directly improves insulin sensitivity and glycemic control in type 2 diabetes.

But the magnitude of weight loss exceeded what any prior diabetes medication had achieved. In SURPASS-3, patients on tirzepatide 15 mg lost an average of 12.9 kg (28.4 pounds) over 52 weeks, a 13.9% reduction in total body weight.

This prompted Eli Lilly to run a separate trial program (SURMOUNT) enrolling non-diabetic patients with obesity. SURMOUNT-1 (N = 2,539, 72 weeks) showed:

• Tirzepatide 5 mg: 15.0% total body weight loss
• Tirzepatide 10 mg: 19.5% total body weight loss
• Tirzepatide 15 mg: 20.9% total body weight loss
• Placebo: 3.1% total body weight loss

These results led to FDA approval of tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

The regulatory distinction exists because FDA approvals are indication-specific. The same molecule requires separate New Drug Applications (NDAs) for different uses. Mounjaro's NDA covers diabetes. Zepbound's NDA covers obesity.

Clinically, the drugs are identical. The dosing is identical. The side effect profile is identical. The only difference is the label on the box and the insurance billing code.

Off-label prescribing: when providers use Mounjaro for weight loss

Off-label prescribing is legal and common in U.S. medical practice. Once a drug is FDA-approved for any indication, providers can prescribe it for other conditions based on clinical judgment and available evidence.

Mounjaro is frequently prescribed off-label for weight loss in non-diabetic patients, particularly when:

1. Insurance covers Mounjaro but not Zepbound. Many insurance formularies added Mounjaro for diabetes before Zepbound launched. Some plans still exclude Zepbound while covering Mounjaro with prior authorization.

1. The patient has prediabetes (A1C 5.7 to 6.4%). This population sits in a gray zone. They don't meet the FDA definition of type 2 diabetes (A1C ≥6.5%), but they have measurable insulin resistance. Providers often prescribe Mounjaro off-label here with the dual goal of preventing diabetes progression and achieving weight loss.

1. The patient has metabolic syndrome without frank diabetes. Elevated triglycerides, low HDL, hypertension, and central obesity often cluster together. Tirzepatide addresses multiple components simultaneously.

1. Zepbound is unavailable due to supply constraints. During periods when Zepbound is on the FDA drug shortage list but Mounjaro is not, providers prescribe Mounjaro off-label to maintain continuity of care.

The clinical evidence supporting off-label use is strong. The SURMOUNT trials demonstrated efficacy in non-diabetic patients. The mechanism of action (GLP-1 and GIP receptor activation) doesn't depend on baseline glucose levels.

The ethical and practical question is cost and access. Mounjaro's list price is $1,069.08 per month. Zepbound's list price is $1,059.87 per month. Without insurance coverage, off-label use of Mounjaro offers no cost advantage over on-label use of Zepbound.

Mounjaro vs Zepbound: identical molecule, different regulatory paths

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
FDA approval date	May 2022	November 2023
Approved indication	Type 2 diabetes	Chronic weight management
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Dosing schedule	Once weekly subcutaneous	Once weekly subcutaneous
List price (April 2026)	$1,069.08/month	$1,059.87/month
Insurance coverage (typical)	Covered for diabetes with PA	Covered for obesity with PA (less common)
Boxed warning	Thyroid C-cell tumors (rodent data)	Thyroid C-cell tumors (rodent data)
Contraindications	MEN2, personal/family hx medullary thyroid cancer	MEN2, personal/family hx medullary thyroid cancer

The only substantive difference is the patient population studied in the phase 3 trials. Mounjaro's approval relied on SURPASS (diabetic patients). Zepbound's approval relied on SURMOUNT (non-diabetic patients with obesity).

From a pharmacology standpoint, the drugs are bioequivalent. A 10 mg dose of Mounjaro produces the same plasma tirzepatide concentration, receptor occupancy, and clinical effect as a 10 mg dose of Zepbound.

The brand-name distinction creates confusion for patients and administrative burden for providers, who must navigate different prior authorization pathways, formulary restrictions, and billing codes for the same molecule.

What most articles get wrong about GIP receptor activation

The most common error in popular explanations of tirzepatide is the claim that "GIP helps with weight loss by reducing appetite."

This is backward.

GIP's primary metabolic role is stimulating insulin secretion in response to food intake, particularly fat and carbohydrate. In isolation, GIP activation in animal models led to weight gain, not weight loss, which is why early drug development efforts focused on GIP antagonists.

The breakthrough insight from tirzepatide development was that GIP activation in the context of simultaneous GLP-1 activation produces a synergistic effect that enhances weight loss beyond what GLP-1 alone achieves.

The mechanism appears to involve:

1. Enhanced insulin sensitivity in adipose tissue. GIP receptors on fat cells, when activated alongside GLP-1 signaling, improve glucose uptake and reduce lipolysis-induced insulin resistance (Samms et al., Science Translational Medicine 2021).

1. Central nervous system effects. GIP receptors in the brain's appetite centers interact with GLP-1 signaling to amplify satiety. The effect is not additive but multiplicative (Coskun et al., Science Translational Medicine 2018).

1. Increased energy expenditure. GIP activation appears to increase thermogenesis in brown adipose tissue, though this mechanism is still being characterized in human studies.

The key point: GIP is not "the weight loss receptor." GLP-1 is not "the diabetes receptor." Both receptors contribute to both effects, and the dual activation produces outcomes superior to either pathway alone.

This matters clinically because it explains why tirzepatide outperforms semaglutide (a pure GLP-1 agonist) in head-to-head trials despite semaglutide being a highly effective medication in its own right.

The compounded tirzepatide option: when and why it's prescribed

Compounded tirzepatide is prepared by state-licensed 503B compounding pharmacies in response to individual prescriptions. It is not FDA-approved and is not interchangeable with Mounjaro or Zepbound.

Compounded versions are prescribed when:

1. Brand-name products are on the FDA drug shortage list. Both Mounjaro and Zepbound have appeared on the shortage list intermittently since 2023. During shortage periods, FDA allows compounding pharmacies to prepare tirzepatide under Section 503B of the Federal Food, Drug, and Cosmetic Act.

1. Cost is prohibitive. Compounded tirzepatide typically costs $250 to $400 per month compared to $1,000+ for brand-name products. For patients without insurance coverage, compounded versions provide the only financially sustainable access.

1. Insurance denies coverage. Many commercial plans and Medicare Part D exclude GLP-1 medications for weight loss. Patients who meet clinical criteria but face formulary restrictions often turn to compounded alternatives.

1. Dosing flexibility is needed. Compounded tirzepatide can be prepared in doses between the standard increments (for example, 6 mg or 8 mg) to optimize tolerance during titration.

The clinical evidence base for compounded tirzepatide is the same as for brand-name products because the active ingredient is identical. The difference lies in manufacturing oversight. Brand-name products undergo FDA batch testing, stability studies, and post-market surveillance. Compounded products are subject to state pharmacy board regulation and USP 797 sterile compounding standards but do not undergo the same federal review process.

Patients considering compounded tirzepatide should verify that the pharmacy holds an active 503B registration with FDA and state licensure, uses tirzepatide powder from an FDA-registered supplier, and provides certificates of analysis for each batch.

Who should not take Mounjaro or tirzepatide

Absolute contraindications (do not prescribe):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity reaction to tirzepatide

Relative contraindications (use with caution or avoid):

• History of pancreatitis. GLP-1 receptor agonists carry a small but measurable increased risk of acute pancreatitis. Tirzepatide was not studied in patients with prior pancreatitis. Most guidelines recommend avoiding GLP-1 agonists in this population.

• Severe gastroparesis. Tirzepatide slows gastric emptying, which can worsen pre-existing gastroparesis. Patients with diabetic gastroparesis should be evaluated carefully before starting treatment.

• Active gallbladder disease. Rapid weight loss increases gallstone formation risk. Patients with symptomatic cholelithiasis should address gallbladder issues before starting tirzepatide.

• Pregnancy or breastfeeding. Tirzepatide is not recommended during pregnancy. Women of childbearing potential should use contraception. The medication should be discontinued at least 2 months before a planned pregnancy due to its long half-life.

• Severe renal impairment (eGFR <15 mL/min). Tirzepatide has not been studied in end-stage renal disease. Use in dialysis patients is not recommended.

• Proliferative diabetic retinopathy. Rapid glucose reduction has been associated with temporary worsening of diabetic retinopathy. Patients with active proliferative retinopathy should be monitored closely by ophthalmology during titration.

Age considerations: Mounjaro is approved for adults 18 and older. Pediatric trials are ongoing but no approval exists for patients under 18 as of April 2026.

The dosing ladder: how treatment typically progresses

Tirzepatide follows a fixed dose-escalation schedule designed to minimize gastrointestinal side effects while achieving therapeutic effect.

Standard titration schedule:

Week	Dose	Purpose
1-4	2.5 mg once weekly	Initiation dose (sub-therapeutic for most patients)
5-8	5 mg once weekly	First therapeutic dose
9-12	7.5 mg once weekly	Escalation (if needed for glycemic control or weight loss)
13-16	10 mg once weekly	Escalation
17-20	12.5 mg once weekly	Escalation
21+	15 mg once weekly	Maximum approved dose

The 2.5 mg starting dose is intentionally sub-therapeutic. Its purpose is receptor priming and GI adaptation, not clinical effect. Most patients see minimal weight loss or A1C reduction at 2.5 mg.

Clinical effect typically begins at 5 mg. In the SURPASS trials, 5 mg produced meaningful A1C reduction (1.9 percentage points) and weight loss (7 to 8 kg over 40 weeks).

Whether to escalate beyond 5 mg depends on:

• Glycemic control. If A1C is at goal (<7% for most patients, <6.5% for some), staying at 5 mg is reasonable.
• Weight loss trajectory. If weight loss stalls before reaching goal, escalation often restarts progress.
• Tolerability. If nausea, vomiting, or reflux is problematic at 5 mg, escalation may worsen symptoms.

The median dose in real-world prescribing data is 10 mg. About 30% of patients escalate to 15 mg. About 20% stay at 5 or 7.5 mg long-term due to either adequate response or tolerability limits.

FormBlends clinical pattern: Across our compounded tirzepatide patient population, the most common long-term maintenance dose is 7.5 to 10 mg. Patients who start at 2.5 mg and escalate every 4 weeks typically reach their maintenance dose by week 12 to 16. The minority who escalate to 15 mg usually do so because weight loss plateaued at 10 mg, not because glycemic control was inadequate.

Insurance coverage patterns: why the brand name matters

Insurance coverage for tirzepatide is fragmented and rapidly evolving. As of April 2026:

Medicare Part D:

• Covers Mounjaro for type 2 diabetes (on-label use)
• Does NOT cover Zepbound or any GLP-1 medication for weight loss due to the statutory exclusion of weight-loss drugs from Part D formularies
• Does NOT cover compounded tirzepatide

Commercial insurance (employer-sponsored plans):

• 68% of plans cover Mounjaro for diabetes with prior authorization (PA)
• 34% of plans cover Zepbound for obesity with PA
• PA requirements typically include BMI ≥30 (or ≥27 with comorbidity), documented diet and exercise attempts, and sometimes a requirement to try older medications first (metformin for diabetes, phentermine for obesity)
• Step therapy is common: must try semaglutide before tirzepatide

Medicaid:

• Coverage varies by state
• 31 states cover Mounjaro for diabetes as of April 2026
• 12 states cover Zepbound for obesity
• Many states exclude all weight-loss medications regardless of clinical indication

Prior authorization denial rates:

• First-submission denial rate for Mounjaro (diabetes indication): 22%
• First-submission denial rate for Zepbound (obesity indication): 47%
• Appeal success rate: 61% for Mounjaro, 38% for Zepbound

The coverage gap creates perverse incentives. A patient with obesity (BMI 32) and prediabetes (A1C 6.2%) does not qualify for Mounjaro coverage (A1C too low) or Zepbound coverage (plan excludes it). The same patient would qualify for Mounjaro if their A1C crosses 6.5%, even though earlier intervention would prevent diabetes progression.

This is why compounded tirzepatide has become the primary access pathway for many patients. The out-of-pocket cost is lower than brand-name copays for most patients without coverage.

FAQ

What is Mounjaro prescribed for? Mounjaro is FDA-approved for improving blood sugar control in adults with type 2 diabetes as an adjunct to diet and exercise. It is not approved for weight loss in non-diabetic patients, though the same molecule is sold as Zepbound for that indication.

Can Mounjaro be used for weight loss? Yes, off-label. Providers frequently prescribe Mounjaro for weight loss in non-diabetic patients, particularly when insurance covers Mounjaro but not Zepbound. The clinical evidence from the SURMOUNT trials shows tirzepatide produces 15 to 21% total body weight loss in non-diabetic patients with obesity.

What is the difference between Mounjaro and Zepbound? None, clinically. Both contain tirzepatide at identical doses. Mounjaro is FDA-approved for diabetes. Zepbound is FDA-approved for weight loss. The drugs are bioequivalent and produce the same effects. The distinction is regulatory and insurance-related.

How does Mounjaro work? Mounjaro activates GLP-1 and GIP receptors, which increases insulin secretion when blood sugar is elevated, suppresses glucagon, slows gastric emptying, and signals satiety in the brain. The dual-receptor activation produces better blood sugar control and more weight loss than GLP-1-only medications like semaglutide.

What conditions does Mounjaro treat? Mounjaro is approved only for type 2 diabetes. It is used off-label for obesity, prediabetes, metabolic syndrome, and polycystic ovary syndrome (PCOS) when weight loss and improved insulin sensitivity are therapeutic goals.

Is Mounjaro the same as Ozempic? No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Tirzepatide produces more weight loss than semaglutide in head-to-head trials (SURPASS-2 showed 11.2 kg vs 5.7 kg at comparable doses).

How much weight do people lose on Mounjaro? In the SURPASS trials (diabetic patients), average weight loss ranged from 7 kg (15 pounds) at 5 mg to 13 kg (29 pounds) at 15 mg over 40 to 52 weeks. In the SURMOUNT trials (non-diabetic patients with obesity), average weight loss was 15% to 21% of total body weight at 72 weeks.

What is the starting dose of Mounjaro? 2.5 mg once weekly for the first 4 weeks. This is a sub-therapeutic initiation dose designed to minimize nausea and other GI side effects. The dose escalates to 5 mg at week 5, which is the first therapeutic dose for most patients.

Can you take Mounjaro if you don't have diabetes? Yes, off-label. Many providers prescribe Mounjaro for weight loss in non-diabetic patients. The FDA-approved option for non-diabetic patients is Zepbound, which contains the same active ingredient. Compounded tirzepatide is another option when brand-name products are unavailable or unaffordable.

Does Mounjaro lower blood sugar in non-diabetic people? Tirzepatide's insulin-stimulating effect is glucose-dependent, meaning it only increases insulin when blood sugar is elevated. In non-diabetic patients with normal fasting glucose, tirzepatide does not cause hypoglycemia. It may modestly lower fasting glucose from the high-normal range (95 to 100 mg/dL) to the mid-normal range (85 to 90 mg/dL).

What are the most common side effects of Mounjaro? Nausea (20 to 30% of patients), diarrhea (15 to 20%), vomiting (8 to 12%), constipation (6 to 10%), and abdominal pain (8%). Most GI side effects are worst during the first 4 to 8 weeks and during dose escalations. They typically improve with continued use.

How long does it take for Mounjaro to work? For blood sugar control, A1C reduction is measurable within 4 weeks and reaches maximum effect by 12 to 16 weeks. For weight loss, most patients see 1 to 2 pounds per week starting at week 5 to 8 (when the dose reaches 5 mg or higher). Weight loss continues for 52 to 72 weeks before plateauing.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
7. Frias JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017.
8. Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020.
9. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022.
10. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
12. FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated April 2026.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.